Therapeutics News and Research

RSS

Vaccine candidate targeting SARS-CoV-2 nucleocapsid protein elicits protective immune response in animal model

New preclinical results from a study led by David Masopust of the University of Minnesota in Minneapolis, USA, show that a Had5-based vaccine targeting the nucleocapsid protein can also elicit a protective immune response.

3 May 2021

Comprehensive "cell atlas" shows how COVID-19 can lead to organ failure and death

Scientists from several hospitals and research centers have shown what happens in individual cells of patients who died of COVID-19. In a study published in Nature, the researchers describe how infected cells from multiple organs exhibited a range of molecular and genomic changes.

3 May 2021

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

A study recently published in the journal Matter has demonstrated the development and validation of a nanoparticle-based formulation, capable of completely inhibiting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection blocking the interaction between viral spike protein and host cell angiotensin-converting enzyme 2 (ACE2).

3 May 2021

Could CRISPR be used as a SARS-CoV-2 antiviral?

The potential of using this gene manipulation technology as a SARS-CoV-2 inhibitor or prophylactic is investigated in a review recently uploaded to the journal Experimental Biology and Medicine (April 25th, 2021) by Arnab Banerjee and colleagues.

2 May 2021

Arresting tumor growth for a variety of cancers through T cell engineering

Through T cell engineering, researchers at Virginia Commonwealth University Massey Cancer Center show that it's possible to arrest tumor growth for a variety of cancers and squash the spread of cancer to other tissues.

30 Apr 2021

Applications of nanoparticles in combating COVID-19

Researchers review the various properties and use of nanoparticles in targeting SARS-CoV-2 and how they could be used to develop new therapeutics and diagnostics for SARS-CoV-2.

30 Apr 2021

Hepatitis C antivirals synergize with remdesivir to inhibit SARS-CoV-2 in vitro

A new study sheds light on the potential of drug combinations to stem viral transmission and treat patients with COVID-19. It also shows that four drugs used to treat hepatitis C synergize with remdesivir to make it up to ten times more effective at inhibiting SARS-CoV-2 in cell cultures.

30 Apr 2021

ProductLife Group Enters US Market with Acquisition of Leading Regulatory Drug Development Consultancy DS InPharmatics (DSI)

ProductLife Group (PLG) has taken the next step in its evolution as a global leader in end-to-end regulatory compliance services.

From DSI, a PLG Company 30 Apr 2021

New study reveals mechanisms that result in lethal COVID-19

A new study is drawing the most detailed picture yet of SARS-CoV-2 infection in the lung, revealing mechanisms that result in lethal COVID-19, and may explain long-term complications and show how COVID-19 differs from other infectious diseases.

30 Apr 2021

Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant

Researchers in the Republic of Korea (South Korea), The Netherlands, and South Africa have demonstrated the potential of the monoclonal antibody CT-P59 as an effective therapeutic for coronavirus disease 2019 (COVID-19) caused by the South African B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

29 Apr 2021

New genetically encoded sensor helps detect drugs of abuse

A genetically encoded sensor to detect hallucinogenic compounds has been developed by researchers at the University of California, Davis. Named psychLight, the sensor could be used in discovering new treatments for mental illness, in neuroscience research and to detect drugs of abuse. The work is published April 28 in the journal Cell.

29 Apr 2021

Single protein could be a new target for delaying onset of aging symptoms in the brain

It is not every day that scientists come across a phenomenon so fundamental that it is observed across fruit flies, rodents and humans.

29 Apr 2021

Scientists design 'smart' cellular biosensors for detecting SARS-CoV-2 spike

New research led by Hana El-Samad of the University of California, San Francisco, and the Chan-Zuckerberg Biohub confirmed the beneficial use of an antiviral therapeutic called SARSNotch, which uses a combination of the SynNotch platform and de-novo designed protein binders. SARSNotch uses sentinel T cells to detect and mount a genetic response toward the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

28 Apr 2021

ANTICOV clinical trial to test new treatment for people with mild-to-moderate COVID-19 in Africa

The ANTICOV clinical trial, conducted in 13 African countries, has started the recruitment of participants to test a new drug combination, nitazoxanide + ciclesonide, to treat people with mild-to-moderate COVID-19 before their cases become severe.

27 Apr 2021

Some heart medications may facilitate SARS-CoV-2 infection through increasing ACE2 receptor levels

An interesting poster, just presented at the annual meeting of the American Society for Pharmacology and Experimental Therapeutics 2021, reports an association between the use of certain heart medications and the risk of COVID-19.

27 Apr 2021

Researchers develop eleven SARS-CoV-2 RBD nanobodies using computational design

To develop therapeutics that block this binding process, a team of researchers recently used an integrated computational approach to design nanobodies (Nbs) against the SARS-CoV-2 RBD, using neutralizing/monoclonal antibodies specific to RBD of the spike protein.

27 Apr 2021

Research suggests that Ginkgo biloba extract contains naturally occurring inhibitors against SARS-CoV-2

Researchers at Shihezi University in China found that Gingko Biloba leaves extract contains the most potent SARS-CoV-2 3-Chymotrypsin-like protease (3CLpro). This virally encoded main proteinase is essential for viral replication in coronaviruses.

27 Apr 2021

Study reveals a hidden role of circulating microRNA as a driver of SARS-CoV-2 infection

In a methodological tour-de-force study, a large group of researchers from the USA and the United Kingdom analyzed patient transcriptomic data in-depth and discovered a circulating microRNA (miR-2392) that is directly implicated in the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) machinery during the infection process.

26 Apr 2021

A new roadmap for advancing TBI care

Brain research and advocacy nonprofit Cohen Veterans Bioscience (CVB) today announced the launch of a National TBI Precision Solutions Research Roadmap, with the advent of the first in a series of publications resulting from its Brain Trauma Blueprint framework program.

26 Apr 2021

Surge of pediatric patients with diabetic ketoacidosis during COVID-19 pandemic

According to the Centers for Disease Control and Prevention (CDC), children generally appear to be less severely impacted by COVID-19 than adults.

26 Apr 2021

Therapeutics News and Research

Vaccine candidate targeting SARS-CoV-2 nucleocapsid protein elicits protective immune response in animal model

Comprehensive "cell atlas" shows how COVID-19 can lead to organ failure and death

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

Could CRISPR be used as a SARS-CoV-2 antiviral?

Arresting tumor growth for a variety of cancers through T cell engineering

Applications of nanoparticles in combating COVID-19

Hepatitis C antivirals synergize with remdesivir to inhibit SARS-CoV-2 in vitro

ProductLife Group Enters US Market with Acquisition of Leading Regulatory Drug Development Consultancy DS InPharmatics (DSI)

New study reveals mechanisms that result in lethal COVID-19

Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant

New genetically encoded sensor helps detect drugs of abuse

Single protein could be a new target for delaying onset of aging symptoms in the brain

Scientists design 'smart' cellular biosensors for detecting SARS-CoV-2 spike

ANTICOV clinical trial to test new treatment for people with mild-to-moderate COVID-19 in Africa

Some heart medications may facilitate SARS-CoV-2 infection through increasing ACE2 receptor levels

Researchers develop eleven SARS-CoV-2 RBD nanobodies using computational design

Research suggests that Ginkgo biloba extract contains naturally occurring inhibitors against SARS-CoV-2

Study reveals a hidden role of circulating microRNA as a driver of SARS-CoV-2 infection

A new roadmap for advancing TBI care

Surge of pediatric patients with diabetic ketoacidosis during COVID-19 pandemic

Understanding the DNA Damage Response in Innate Immunity eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News